Important Information for Cassava Sciences, Inc. Securities Purchasers: Deadline Approaching for Lead Plaintiff Selection in Class Action Lawsuit
New York, NY – Rosen Law Firm, a global investor rights law firm, alerts investors that the deadline to seek appointment as lead plaintiff in a securities class action lawsuit against Cassava Sciences, Inc. (NASDAQ: SAVA) is rapidly approaching. The Class Period for this action spans from February 7, 2024, to November 24, 2024. If you purchased or acquired Cassava securities during this timeframe, you may be entitled to compensation without any out-of-pocket costs or fees.
About the Class Action Lawsuit
The lawsuit, which was filed in the United States District Court for the Eastern District of Texas, alleges that Cassava Sciences and certain of its executives made false and misleading statements regarding the efficacy and safety of its drug, Pimavanserin, and the company’s financial performance. Specifically, the complaint asserts that the defendants failed to disclose material information about the clinical trial data for Pimavanserin, which eventually led to its suspension and delisting from the Nasdaq stock exchange.
Impact on Individual Investors
If you purchased or acquired Cassava securities during the Class Period, you may have suffered significant financial losses. The lead plaintiff is a court-appointed representative who acts on behalf of the class in the lawsuit. By seeking appointment as the lead plaintiff, you may be able to help direct the litigation and potentially influence the outcome, including any potential settlement. Moreover, the lead plaintiff may be entitled to a larger share of any recovery, including any damages, fees, or costs.
- To be eligible to serve as the lead plaintiff, you must meet specific requirements, such as holding a significant number of shares during the Class Period and not having sold your shares before the filing of the lawsuit.
- If you wish to be considered as the lead plaintiff or have any questions regarding your eligibility, please contact Rosen Law Firm as soon as possible.
Impact on the World
The outcome of this class action lawsuit could have far-reaching implications for the pharmaceutical industry and the investing public. By holding Cassava Sciences and its executives accountable for their alleged misrepresentations, the lawsuit could deter similar misconduct in the future and promote transparency and accuracy in corporate disclosures. Moreover, it could potentially lead to increased investor confidence and trust in the stock market.
Conclusion
If you purchased or acquired Cassava Sciences securities during the Class Period, you may be entitled to compensation without any out-of-pocket costs or fees. The deadline to seek appointment as the lead plaintiff is rapidly approaching, so it is essential to act quickly. Rosen Law Firm encourages investors to contact them for more information about the lawsuit and their eligibility to serve as the lead plaintiff.
Additionally, the potential impact of this lawsuit on the pharmaceutical industry and the investing public underscores the importance of corporate transparency and accurate disclosures. By holding companies accountable for their actions, investors can make informed decisions and protect their investments. For more information, please contact Rosen Law Firm at (866) 767-3653 or fill out the form on their website.
About Rosen Law Firm: Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 in the number of securities class action settlements in 2019 and 2020. The firm has recovered hundreds of millions of dollars for investors.
